1. Lupus around the World
- Author
-
N Gorodnitski, Riva Brik, M Rubenstein, Tsivia Tauber, Yackov Berkun, Masza Mukamel, Liora Harel, Yosef Uziel, Joseph Press, Yaakov Naparstek, Navon P, Shai Padeh, Dror Mevorach, Judith Barash, and Philip J. Hashkes
- Subjects
030203 arthritis & rheumatology ,Pediatrics ,medicine.medical_specialty ,Systemic lupus erythematosus ,business.industry ,030204 cardiovascular system & hematology ,medicine.disease ,National cohort ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Cohort ,Immunology ,medicine ,skin and connective tissue diseases ,business - Abstract
The aim of this study was to describe the clinical manifestations and outcomes of a national cohort of childhood systemic lupus erythematosus (cSLE). All cases of cSLE registered in the Israeli national registry of children with rheumatic diseases between 1987–2003 were examined for disease activity and damage by the SLE disease activity index (SLEDAI) and SLE collaborating clinics/American College of Rheumatology (SLICC/ACR) damage index. Demographic, clinical, laboratory and treatment factors were analysed for their effect on the outcome. One-hundred and two patients were identified, 81% females, with a mean age at diagnosis of 13.3 ± 2.6 years. The mean SLEDAI score was 17.2 ± 9.0 (range 2–60). Fifty four patients were followed for at least five years. The mean SLEDAI decreased to 7.6 ± 6.3 (0–29) and the mean SLICC/ACR damage index was 0.7 ± 1.6 (0–8). Five patients developed chronic renal failure. No patients died. No factors were found to be significantly associated with the outcome except the initial SLEDAI score. The five-year outcome of our national cSLE cohort was good; with relatively low activity and minimal damage in most patients. The initial SLEDAI predicted the development of late damage.
- Published
- 2007
- Full Text
- View/download PDF